An open-label study of botulinum toxin A for treatment of tardive dystonia

D. Tarsy, David Myland Kaufman, K. D. Sethi, M. H. Rivner, E. Molho, S. Factor

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Tardive dystonia is a form of tardive dyskinesia for which there is little satisfactory treatment. We reviewed our experience at four movement disorder centers in the treatment of tardive dystonia with botulinum toxin A (BTX-A). Thirty-four patients with relatively localized tardive dystonia unresponsive to oral medications were treated with injections of BTX-A into dystonic muscles. Cervical dystonia was the most frequent manifestation of tardive dystonia in this group of patients. There was marked or moderate improvement in 29 of 34 patients. Eighteen of 24 patients with cervical dysionia showed either marked or moderate improvement. In this retrospective review, BTX-A provided useful symptomatic treatment for localized dystonia in patients with tardive dystonia unresponsive to other treatment. A controlled, prospective trial of BTX-A in tardive dystonia is warranted.

Original languageEnglish (US)
Pages (from-to)90-93
Number of pages4
JournalClinical Neuropharmacology
Volume20
Issue number1
StatePublished - 1997

Fingerprint

Type A Botulinum Toxins
Therapeutics
Torticollis
Dystonia
Movement Disorders
Tardive Dyskinesia
Muscles
Injections

Keywords

  • Botulinum toxin
  • Neuroleptic drugs
  • Tardive dyskinesia
  • Tardive dystonia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Tarsy, D., Kaufman, D. M., Sethi, K. D., Rivner, M. H., Molho, E., & Factor, S. (1997). An open-label study of botulinum toxin A for treatment of tardive dystonia. Clinical Neuropharmacology, 20(1), 90-93.

An open-label study of botulinum toxin A for treatment of tardive dystonia. / Tarsy, D.; Kaufman, David Myland; Sethi, K. D.; Rivner, M. H.; Molho, E.; Factor, S.

In: Clinical Neuropharmacology, Vol. 20, No. 1, 1997, p. 90-93.

Research output: Contribution to journalArticle

Tarsy, D, Kaufman, DM, Sethi, KD, Rivner, MH, Molho, E & Factor, S 1997, 'An open-label study of botulinum toxin A for treatment of tardive dystonia', Clinical Neuropharmacology, vol. 20, no. 1, pp. 90-93.
Tarsy, D. ; Kaufman, David Myland ; Sethi, K. D. ; Rivner, M. H. ; Molho, E. ; Factor, S. / An open-label study of botulinum toxin A for treatment of tardive dystonia. In: Clinical Neuropharmacology. 1997 ; Vol. 20, No. 1. pp. 90-93.
@article{1944b9371bcc45e2a76c7bbdcb5f6615,
title = "An open-label study of botulinum toxin A for treatment of tardive dystonia",
abstract = "Tardive dystonia is a form of tardive dyskinesia for which there is little satisfactory treatment. We reviewed our experience at four movement disorder centers in the treatment of tardive dystonia with botulinum toxin A (BTX-A). Thirty-four patients with relatively localized tardive dystonia unresponsive to oral medications were treated with injections of BTX-A into dystonic muscles. Cervical dystonia was the most frequent manifestation of tardive dystonia in this group of patients. There was marked or moderate improvement in 29 of 34 patients. Eighteen of 24 patients with cervical dysionia showed either marked or moderate improvement. In this retrospective review, BTX-A provided useful symptomatic treatment for localized dystonia in patients with tardive dystonia unresponsive to other treatment. A controlled, prospective trial of BTX-A in tardive dystonia is warranted.",
keywords = "Botulinum toxin, Neuroleptic drugs, Tardive dyskinesia, Tardive dystonia",
author = "D. Tarsy and Kaufman, {David Myland} and Sethi, {K. D.} and Rivner, {M. H.} and E. Molho and S. Factor",
year = "1997",
language = "English (US)",
volume = "20",
pages = "90--93",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - An open-label study of botulinum toxin A for treatment of tardive dystonia

AU - Tarsy, D.

AU - Kaufman, David Myland

AU - Sethi, K. D.

AU - Rivner, M. H.

AU - Molho, E.

AU - Factor, S.

PY - 1997

Y1 - 1997

N2 - Tardive dystonia is a form of tardive dyskinesia for which there is little satisfactory treatment. We reviewed our experience at four movement disorder centers in the treatment of tardive dystonia with botulinum toxin A (BTX-A). Thirty-four patients with relatively localized tardive dystonia unresponsive to oral medications were treated with injections of BTX-A into dystonic muscles. Cervical dystonia was the most frequent manifestation of tardive dystonia in this group of patients. There was marked or moderate improvement in 29 of 34 patients. Eighteen of 24 patients with cervical dysionia showed either marked or moderate improvement. In this retrospective review, BTX-A provided useful symptomatic treatment for localized dystonia in patients with tardive dystonia unresponsive to other treatment. A controlled, prospective trial of BTX-A in tardive dystonia is warranted.

AB - Tardive dystonia is a form of tardive dyskinesia for which there is little satisfactory treatment. We reviewed our experience at four movement disorder centers in the treatment of tardive dystonia with botulinum toxin A (BTX-A). Thirty-four patients with relatively localized tardive dystonia unresponsive to oral medications were treated with injections of BTX-A into dystonic muscles. Cervical dystonia was the most frequent manifestation of tardive dystonia in this group of patients. There was marked or moderate improvement in 29 of 34 patients. Eighteen of 24 patients with cervical dysionia showed either marked or moderate improvement. In this retrospective review, BTX-A provided useful symptomatic treatment for localized dystonia in patients with tardive dystonia unresponsive to other treatment. A controlled, prospective trial of BTX-A in tardive dystonia is warranted.

KW - Botulinum toxin

KW - Neuroleptic drugs

KW - Tardive dyskinesia

KW - Tardive dystonia

UR - http://www.scopus.com/inward/record.url?scp=0031026930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031026930&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 90

EP - 93

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 1

ER -